Partner Fred Geilfuss and Special Counsel Kyle Faget were quoted in a Modern Healthcare article, “ACA repeal wouldn’t stop transition to value-based payment, efforts to lower drug spending,” about what would happen if the Affordable Care Act is ultimately held to be unconstitutional.
Geilfuss said providers that have already invested in the infrastructure, technology and staff to facilitate new payment models like accountable care organizations, bundled payments and Medicare Shared Savings would probably continue to do so. “To just throw that out seems very unlikely,” he said. “There would be a lot of people who are motivated to figure out a way to continue that momentum.”
Faget said if the ACA is found to be unconstitutional, Congress would probably reenact the Biologics Price Competition and Innovation Act of 2009, which was folded into the ACA, as a standalone law. The act allows the Food and Drug Administration to approve biosimilars, which mimic expensive biologic drugs made from living organisms. “Biosimilars are absolutely a big part of reducing drug prices,” she said.
Geilfuss said providers that have already invested in the infrastructure, technology and staff to facilitate new payment models like accountable care organizations, bundled payments and Medicare Shared Savings would probably continue to do so. “To just throw that out seems very unlikely,” he said. “There would be a lot of people who are motivated to figure out a way to continue that momentum.”
Faget said if the ACA is found to be unconstitutional, Congress would probably reenact the Biologics Price Competition and Innovation Act of 2009, which was folded into the ACA, as a standalone law. The act allows the Food and Drug Administration to approve biosimilars, which mimic expensive biologic drugs made from living organisms. “Biosimilars are absolutely a big part of reducing drug prices,” she said.
People
Related News
24 April 2024
In the News
Judith Waltz Discusses Nursing Home Staffing Mandate, Potential Legal Challenges
Foley & Lardner LLP partner Judith Waltz offers insight on a new nursing home staffing rule from the U.S. Department of Health and Human Services and its impact on the industry in the Bloomberg Law article, “Nursing Homes, HHS on Collision Path Over Staffing Mandate.”
23 April 2024
In the News
David Sanders Discusses Lessons Learned from General Counsel Leadership Program
Foley & Lardner LLP partner David Sanders recently joined a panel discussion with members of The Vanguard Network’s General Counsels Advisory Group to discuss the evolving role of the general counsel.
23 April 2024
In the News
Claire Marblestone Discusses HHS Final Rule on Protected Health Information Disclosure
Foley & Lardner LLP Claire Marblestone assessed the U.S. Department of Health and Human Services’ final rule that bars providers, health plans, and other entities covered by the Health Insurance Portability and Accountability Act from disclosing protected health information in a Healthcare Dive article.